PHRIXUS PHARMACEUTICALS, INC.

Company Information

Company Name
PHRIXUS PHARMACEUTICALS, INC.
Address
1600 HURON PARKWAY BLDG. 520, 2ND FLOOR
ANN ARBOR, MI, 48109-5001
Phone
1 734-358-9015
URL
n/a
DUNS
620122676
Number of Employees
2
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$2,078,319.00
5
STTR Phase I
$306,708.00
1

Award List

  1. Chronic Treatment of Heart Failure With Poloxamer-188

    Amount: $215,084.00

    DESCRIPTION (provided by applicant): Heart failure (HF) is a major medical problem in the United States affecting more than 5 million patients. It is expected to impact 11 million patients by 2011. Of ...

    SBIR Phase I 2007 Department of Health and Human Services
  2. Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis

    Amount: $277,646.00

    DESCRIPTION (provided by applicant): Project Summary. This application is focused on preventing adverse events associated with chronic peritoneal dialysis (PD), a renal replacement the ...

    SBIR Phase I 2008 Department of Health and Human Services
  3. Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H

    Amount: $379,487.00

    DESCRIPTION (provided by applicant): This application focuses on initial preclinical steps required to develop Poloxamer-188 (P-188) for the treatment of heart failure (HF) associated with Duchene and ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo

    Amount: $583,225.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop Poloxamer-188 (P-188) for the delay or prevention of respiratory deficits in patients with Duchenne muscular dystr ...

    SBIR Phase I 2011 Department of Health and Human Services
  5. Poloxamer 188 mechanism of action in ischemic heart failure.

    Amount: $306,708.00

    DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxyge ...

    STTR Phase I 2010 Department of Health and Human Services
  6. Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188

    Amount: $622,877.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to obtain FDA approval to market Poloxamer-188 (P- 188) for the prevention and treatment of dilated cardiomyopathy (DCM) and ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government